[mTOR and FTY 720 inhibitors]

Area of Science:

• Immunology
• Pharmacology

Background:

• Sirolimus (rapamycin) is an mTOR inhibitor with dose-dependent side effects, manageable when combined with other immunosuppressants like tacrolimus or cyclosporine.
• Effective sirolimus plasma concentrations range from 5 to 20 ng/ml, varying with combination therapy.
• Sirolimus has demonstrated potential in inhibiting metastatic renal adenocarcinoma in mice, with ongoing research into its effects on angiogenesis, fibrosis, and chronic rejection.

Framework:

• Everolimus (RAD) is an mTOR inhibitor with a short half-life and fewer hematologic effects than sirolimus.
• Therapeutic dosing of everolimus requires plasma concentrations of at least 3 ng/ml to prevent rejection.
• Higher everolimus doses (above 15 ng/ml) are associated with an increased risk of thrombocytopenia.

Implementation:

• FTY720 represents a new class of immunosuppressant with a unique mechanism of action.
• FTY720 enhances chemokine receptor expression on T cells, preventing their involvement in rejection.
• FTY720 possesses a long half-life (108 hours) and minimal risk of drug interactions due to its distinct liver metabolism.

Implications:

• Understanding the pharmacokinetics and pharmacodynamics of sirolimus, everolimus, and FTY720 is crucial for optimizing immunosuppressive therapy.
• FTY720's novel mechanism and favorable drug interaction profile present a promising alternative in immunosuppression.
• Further investigation into sirolimus's complex effects on angiogenesis and fibrosis may reveal new therapeutic strategies.